CBIO CRESCENT BIOPHARMA, INC.
Nasdaq · SEC CIK 1253689 · EDGAR
- Bought, last 12 months
- $30.61M 2 purchases by 2 insiders
- Sold, last 12 months
- $1.51M 14 sales by 7 insiders
- Filings on record
- 112 since 2021-11-18, latest 2026-09-18 16:03
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Harwin Peter Evan | Dir, 10% | $18.24M | — |
| Fairmount Funds Management LLC | Dir, 10% | $12.38M | — |
| Brumm Joshua T | CEO, Dir | — | $920.8K |
| McNeill Jonathan | Pres, COO | — | $446.9K |
| Pinkas Jan | CSO | — | $34.9K |
| Im Ellie Eunkyung | Chief Medical Off | — | $33.1K |
| Bispham Barbara Harlin | See Remarks | — | $33.0K |
| Scalzo Richard William | CFO | — | $30.2K |
| Lynch Ryan | See Remarks | — | $12.7K |
| Doughty Christopher Grant | Chief Business Off | — | — |
Transactions 65
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-18 16:03 | 2026-09-16 | CBIO | Lynch Ryan | See Remarks | S - Sale | $17.90 | -240 | 13.6K | -2% | -$4,296 |
| T | 2026-09-18 16:03 | 2026-09-16 | CBIO | Pinkas Jan | CSO | S - Sale | $17.90 | -658 | 21.6K | -3% | -$11.8K |
| T | 2026-09-18 16:02 | 2026-09-16 | CBIO | Im Ellie Eunkyung | Chief Medical Off | S - Sale | $17.90 | -623 | 21.4K | -3% | -$11.2K |
| T | 2026-09-18 16:02 | 2026-09-16 | CBIO | Scalzo Richard William | CFO | S - Sale | $17.90 | -568 | 19.7K | -3% | -$10.2K |
| T | 2026-09-18 16:02 | 2026-09-16 | CBIO | Bispham Barbara Harlin | See Remarks | S - Sale | $17.90 | -620 | 18.7K | -3% | -$11.1K |
| MT | 2026-09-18 16:02 | 2026-09-16+ | CBIO | Brumm Joshua T | CEO, Dir | S - Sale | $16.91 | -9,447 | 271.8K | -3% | -$159.8K |
| MT | 2026-09-18 16:01 | 2026-09-16+ | CBIO | McNeill Jonathan | Pres, COO | S - Sale | $16.90 | -4,570 | 134.6K | -3% | -$77.2K |
| DI | 2026-07-20 17:30 | 2026-07-16 | CBIO | Fairmount Funds Management LLC | Dir, 10% | P - Purchase | $14.50 | +853.5K | 3.60M | +31% | +$12.38M |
| T | 2026-06-23 16:04 | 2026-06-22 | CBIO | Lynch Ryan | See Remarks | S - Sale | $17.99 | -465 | 13.9K | -3% | -$8,365 |
| T | 2026-06-23 16:04 | 2026-06-22 | CBIO | Pinkas Jan | CSO | S - Sale | $17.99 | -1,288 | 22.2K | -5% | -$23.2K |
| T | 2026-06-23 16:03 | 2026-06-22 | CBIO | Scalzo Richard William | CFO | S - Sale | $17.99 | -1,112 | 20.3K | -5% | -$20.0K |
| T | 2026-06-23 16:03 | 2026-06-22 | CBIO | Bispham Barbara Harlin | See Remarks | S - Sale | $17.99 | -1,218 | 19.3K | -6% | -$21.9K |
| T | 2026-06-23 16:02 | 2026-06-22 | CBIO | Im Ellie Eunkyung | Chief Medical Off | S - Sale | $17.99 | -1,219 | 22.1K | -5% | -$21.9K |
| T | 2026-06-23 16:02 | 2026-06-22 | CBIO | McNeill Jonathan | Pres, COO | S - Sale | $17.99 | -20.5K | 139.2K | -13% | -$369.7K |
| T | 2026-06-23 16:01 | 2026-06-22 | CBIO | Brumm Joshua T | CEO, Dir | S - Sale | $17.99 | -42.3K | 281.2K | -13% | -$761.1K |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Pinkas Jan | CSO | A - Grant | — | +22.5K | 17.5K | New | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Bispham Barbara Harlin | See Remarks | A - Grant | — | +18.4K | 12.4K | New | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Im Ellie Eunkyung | Chief Medical Off | A - Grant | — | +21.3K | 16.3K | New | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Doughty Christopher Grant | Chief Business Off | A - Grant | — | +22.7K | 62.2K | +58% | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Brumm Joshua T | CEO, Dir | A - Grant | — | +55.1K | 323.5K | +21% | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Scalzo Richard William | CFO | A - Grant | — | +19.4K | 19.4K | New | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | Lynch Ryan | See Remarks | A - Grant | — | +12.4K | 12.4K | New | — |
| DM | 2025-12-17 | 2025-12-15 | CBIO | McNeill Jonathan | Pres, COO | A - Grant | — | +25.5K | 159.7K | +19% | — |
| DI | 2025-12-08 | 2025-12-04 | CBIO | Harwin Peter Evan | Dir, 10% | P - Purchase | $13.41 | +1.36M | 2.75M | +98% | +$18.24M |
| DM | 2025-06-17 | 2025-06-13 | CBIO | BVF GP HOLDINGS LLC | 10% | J - Other | — | +1.27M | 707.1K | New | — |
| M | 2024-08-09 | 2024-08-07+ | CBIO | Siren, L.L.C. | 10% | S - Sale | $0.1881 | -322.4K | 6.32M | -5% | -$60.6K |
| M | 2024-08-07 | 2024-08-05+ | CBIO | Invus Public Equities Advisors, LLC | 10% | S - Sale | $0.1875 | -220.3K | 6.64M | -3% | -$41.3K |
| M | 2024-08-05 | 2024-08-01+ | CBIO | Siren, L.L.C. | 10% | S - Sale | $0.2036 | -349.8K | 7.15M | -5% | -$71.2K |
| M | 2024-07-30 | 2024-07-26+ | CBIO | Siren, L.L.C. | 10% | S - Sale | $0.229 | -1.38M | 7.21M | -16% | -$315.9K |
| M | 2024-06-24 | 2024-06-20+ | CBIO | Rock Edwin | Chief Medical Off | P - Purchase | $0.2575 | +305.0K | 680.4K | +81% | +$78.5K |
| 2024-06-20 | 2024-06-18 | CBIO | Hahn Brian M. | CFO, SVP Fin | P - Purchase | $0.25 | +17.5K | 70.6K | +33% | +$4,375 | |
| 2024-04-02 | 2024-03-29 | CBIO | King Rachel K. | Dir | A - Grant | $3.00 | +3,334 | 515.2K | +0.7% | +$10.0K | |
| 2024-04-02 | 2024-03-29 | CBIO | JUNIUS DANIEL M | Dir | A - Grant | $3.00 | +5,209 | 98.5K | +6% | +$15.6K | |
| 2024-04-02 | 2024-03-29 | CBIO | Goldberg Mark Alan | Dir | A - Grant | $3.00 | +4,584 | 24.8K | +23% | +$13.8K | |
| 2024-01-02 | 2023-12-29 | CBIO | King Rachel K. | Dir | A - Grant | $2.36 | +4,238 | 511.9K | +0.8% | +$10.0K | |
| 2024-01-02 | 2023-12-29 | CBIO | Andrews Patricia S | Dir | A - Grant | $2.36 | +5,191 | 58.6K | +10% | +$12.3K | |
| 2024-01-02 | 2023-12-29 | CBIO | Goldberg Mark Alan | Dir | A - Grant | $2.36 | +5,827 | 20.2K | +40% | +$13.8K | |
| 2023-10-03 | 2023-09-30 | CBIO | Goldberg Mark Alan | Dir | A - Grant | $1.50 | +9,167 | 14.4K | +175% | +$13.8K | |
| 2023-10-03 | 2023-09-30 | CBIO | Andrews Patricia S | Dir | A - Grant | $1.50 | +8,167 | 53.4K | +18% | +$12.3K | |
| 2023-10-03 | 2023-09-30 | CBIO | King Rachel K. | Dir | A - Grant | $1.50 | +6,667 | 507.6K | +1% | +$10.0K | |
| M | 2023-09-25 | 2023-09-21+ | CBIO | Rock Edwin | Chief Medical Off | P - Purchase | $1.38 | +65.4K | 345.0K | +23% | +$90.3K |
| D | 2023-06-02 | 2023-06-01 | CBIO | Koenig Scott | Dir | M - OptEx | $0.6 | +21.0K | 36.8K | +133% | +$12.6K |
| 2023-05-18 | 2023-05-17 | CBIO | Hahn Brian M. | CFO, SVP Fin | S - Sale | $1.95 | -3,700 | 53.1K | -7% | -$7,215 | |
| 2023-05-11 | 2023-05-10 | CBIO | JUNIUS DANIEL M | Dir | P - Purchase | $1.56 | +30.0K | 93.2K | +47% | +$46.8K | |
| 2023-05-09 | 2023-05-08 | CBIO | Johnson Bruce S | SVP, Chief Commercial Off | P - Purchase | $1.57 | +13.5K | 139.0K | +11% | +$21.2K | |
| 2023-02-28 | 2023-02-24 | CBIO | Wittouck Amaury | 10% | P - Purchase | $1.70 | +100.0K | 8.59M | +1% | +$170.0K | |
| M | 2023-02-23 | 2023-02-21+ | CBIO | Artal Group S.A. | 10% | P - Purchase | $1.78 | +400.0K | 8.29M | +5% | +$711.0K |
| M | 2023-02-17 | 2023-02-15+ | CBIO | Wittouck Amaury | 10% | P - Purchase | $2.00 | +1.52M | 7.57M | +25% | +$3.03M |
| 2023-02-13 | 2023-02-09 | CBIO | Wittouck Amaury | 10% | P - Purchase | $3.24 | +11.5K | 6.57M | +0.2% | +$37.1K | |
| D | 2023-01-30 | 2023-01-27 | CBIO | Koenig Scott | Dir | M - OptEx | $2.55 | +10.5K | 15.8K | +200% | +$26.8K |
| MI | 2023-01-27 | 2023-01-25+ | CBIO | SANDELL SCOTT D | 10% | S - Sale | $3.14 | -3.65M | 4.38M | -45% | -$11.49M |
| MI | 2023-01-06 | 2023-01-05 | CBIO | SANDELL SCOTT D | 10% | S - Sale | $2.76 | -71.4K | 3.88M | -2% | -$197.0K |
| MI | 2023-01-04 | 2022-12-30+ | CBIO | SANDELL SCOTT D | 10% | S - Sale | $2.98 | -398.1K | 4.78M | -8% | -$1.19M |
| 2022-12-27 | 2022-12-22 | CBIO | Rock Edwin | Chief Medical Off | P - Purchase | $2.25 | +110.0K | 310.0K | +55% | +$247.5K | |
| 2022-11-18 | 2022-11-17 | CBIO | JUNIUS DANIEL M | Dir | P - Purchase | $1.87 | +20.0K | 63.2K | +46% | +$37.4K | |
| M | 2022-11-16 | 2022-11-14+ | CBIO | Rock Edwin | Chief Medical Off | P - Purchase | $1.54 | +200.0K | 200.0K | New | +$309.0K |
| 2022-11-14 | 2022-11-11 | CBIO | PEARSON TIMOTHY R | Dir | P - Purchase | $1.29 | +19.4K | 24.6K | +370% | +$25.0K | |
| 2022-11-14 | 2022-11-11 | CBIO | Semerjian Harout | CEO, Dir | P - Purchase | $1.29 | +25.0K | 25.0K | New | +$32.2K | |
| 2022-11-14 | 2022-11-11 | CBIO | Magnani John L. | CSO, SVP of Research | P - Purchase | $1.17 | +45.0K | 366.1K | +14% | +$52.7K | |
| 2022-11-14 | 2022-11-11 | CBIO | Girard Armand | SVP, Chief Business Off | P - Purchase | $1.05 | +6,500 | 29.2K | +29% | +$6,825 | |
| 2022-11-14 | 2022-11-11 | CBIO | Hahn Brian M. | CFO, SVP Fin | P - Purchase | $1.06 | +20.0K | 56.8K | +54% | +$21.2K | |
| 2022-03-10 | 2022-03-09 | CBIO | Magnani John L. | CSO, SVP of Research | S - Sale | $1.09 | -3,227 | 321.0K | -1.0% | -$3,517 | |
| 2022-03-10 | 2022-03-09 | CBIO | Hahn Brian M. | CFO, SVP Fin | S - Sale | $1.09 | -2,917 | 36.8K | -7% | -$3,180 | |
| 2022-03-10 | 2022-03-09 | CBIO | Girard Armand | SVP, Chief Business Off | S - Sale | $1.09 | -2,339 | 22.7K | -9% | -$2,550 | |
| 2021-11-18 | 2021-11-16 | CBIO | Andrews Patricia S | Dir | P - Purchase | $2.05 | +40.0K | 45.2K | +762% | +$82.0K |
Purchase Sale Sale after option exercise All abbreviations